Johnson & Johnson (JNJ)

USD 156.12

(1.07%)

Net Debt Summary of Johnson & Johnson

  • Johnson & Johnson's latest annual net debt in 2023 was 7.47 Billion USD , down -72.07% from previous year.
  • Johnson & Johnson's latest quarterly net debt in 2024 Q3 was 15.77 Billion USD , down -5.07% from previous quarter.
  • Johnson & Johnson reported annual net debt of 26.75 Billion USD in 2022, up 38.88% from previous year.
  • Johnson & Johnson reported annual net debt of 19.26 Billion USD in 2021, down -9.48% from previous year.
  • Johnson & Johnson reported quarterly net debt of 8.15 Billion USD for 2024 Q1, up 9.18% from previous quarter.
  • Johnson & Johnson reported quarterly net debt of 16.61 Billion USD for 2024 Q2, up 103.62% from previous quarter.

Annual Net Debt Chart of Johnson & Johnson (2023 - 1989)

Historical Annual Net Debt of Johnson & Johnson (2023 - 1989)

Year Net Debt Net Debt Growth
2023 7.47 Billion USD -72.07%
2022 26.75 Billion USD 38.88%
2021 19.26 Billion USD -9.48%
2020 21.28 Billion USD 104.8%
2019 10.39 Billion USD -16.02%
2018 12.37 Billion USD -26.16%
2017 16.75 Billion USD 105.51%
2016 8.15 Billion USD 33.04%
2015 6.12 Billion USD 44.65%
2014 4.23 Billion USD 254.24%
2013 -2.74 Billion USD -319.06%
2012 1.25 Billion USD 125.51%
2011 -4.91 Billion USD -90.36%
2010 -2.58 Billion USD -103.47%
2009 -1.26 Billion USD -217.07%
2008 1.08 Billion USD -38.65%
2007 1.76 Billion USD -29.6%
2006 2.51 Billion USD 118.77%
2005 -13.37 Billion USD -110.29%
2004 -6.35 Billion USD -395.56%
2003 -1.28 Billion USD -203.05%
2002 1.24 Billion USD 227.56%
2001 -976 Million USD -1029.52%
2000 105 Million USD -94.45%
1999 1.89 Billion USD -9.38%
1998 2.08 Billion USD 328.81%
1997 -913 Million USD -436.9%
1996 271 Million USD -77.91%
1995 1.22 Billion USD -50.16%
1994 2.46 Billion USD 20.92%
1993 2.03 Billion USD 23.24%
1992 1.65 Billion USD 18.76%
1991 1.39 Billion USD 1.83%
1990 1.36 Billion USD 6.06%
1989 1.28 Billion USD 25.29%

Peer Net Debt Comparison of Johnson & Johnson

Name Net Debt Net Debt Difference
AbbVie Inc. 46.57 Billion USD 83.954%
Bristol-Myers Squibb Company 30 Billion USD 75.09%
Bristol-Myers Squibb Company Ce 30 Billion USD 75.09%
Eli Lilly and Company 22.4 Billion USD 66.648%
Merck & Co., Inc. 29.35 Billion USD 74.546%
Novartis AG 12.95 Billion USD 42.316%
Organon & Co. 8.06 Billion USD 7.363%
Pfizer Inc. 72.18 Billion USD 89.648%